Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:oxanes
go back to main search page
Accession:CHEBI:46942 term browser browse the term
Definition:Any organic heteromonocyclic compoundthat is oxane or its substituted derivatives.
Synonyms:related_synonym: tetrahydropyrans


show annotations for term's descendants           Sort by:
 
Aurothioglucose term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adipor1 adiponectin receptor 1 multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in decreased expression of ADIPOR1 protein CTD PMID:21382165 NCBI chr13:51,240,470...51,260,233
Ensembl chr13:51,240,911...51,260,228
JBrowse link
G Adipor2 adiponectin receptor 2 multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in decreased expression of ADIPOR2 protein CTD PMID:21382165 NCBI chr 4:151,412,135...151,480,108
Ensembl chr 4:151,414,684...151,428,894
JBrowse link
G As3mt arsenite methyltransferase multiple interactions EXP Aurothioglucose inhibits the reaction [AS3MT protein results in increased methylation of Arsenic] CTD PMID:15025511 NCBI chr 1:266,482,787...266,514,570
Ensembl chr 1:266,482,858...266,514,569
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex multiple interactions ISO Aurothioglucose inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein] CTD PMID:10820281 NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
JBrowse link
G Fas Fas cell surface death receptor multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in decreased expression of FAS protein CTD PMID:21382165 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO Aurothioglucose inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] CTD PMID:23769903 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO [Dexamethasone co-treated with Aurothioglucose] inhibits the reaction [IL1B protein results in increased expression of TYMP mRNA] CTD PMID:15990992 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Lep leptin multiple interactions
increases expression
ISO [Sodium Glutamate co-treated with Aurothioglucose] results in increased expression of LEP mRNA; [Sodium Glutamate co-treated with Aurothioglucose] results in increased expression of LEP protein
Aurothioglucose results in increased expression of LEP mRNA; Aurothioglucose results in increased expression of LEP protein
CTD PMID:7489415, PMID:9794456, PMID:15809509 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Npy neuropeptide Y decreases expression ISO Aurothioglucose results in decreased expression of NPY mRNA CTD PMID:9794456 NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
JBrowse link
G Pomc proopiomelanocortin decreases expression ISO Aurothioglucose results in decreased expression of POMC mRNA CTD PMID:9794456 NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in decreased expression of PPARG protein CTD PMID:21382165 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Retn resistin decreases expression ISO Aurothioglucose results in decreased expression of RETN CTD PMID:15809509 NCBI chr12:2,201,909...2,203,649
Ensembl chr12:2,201,891...2,204,249
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in increased expression of TGFB1 protein CTD PMID:21382165 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions ISO [Dietary Fats co-treated with Aurothioglucose] results in increased expression of TIMP1 protein CTD PMID:21382165 NCBI chr  X:1,364,771...1,369,451
Ensembl chr  X:1,364,786...1,369,384
JBrowse link
G Txnrd1 thioredoxin reductase 1 decreases activity ISO Aurothioglucose results in decreased activity of TXNRD1 protein CTD PMID:21172426 NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
JBrowse link
G Txnrd2 thioredoxin reductase 2 decreases activity ISO Aurothioglucose results in decreased activity of TXNRD2 protein CTD PMID:21172426 NCBI chr11:86,667,994...86,716,063
Ensembl chr11:86,667,997...86,716,254
JBrowse link
G Tymp thymidine phosphorylase multiple interactions ISO [Dexamethasone co-treated with Aurothioglucose] inhibits the reaction [IL1B protein results in increased expression of TYMP mRNA] CTD PMID:15990992 NCBI chr 7:130,342,481...130,347,845
Ensembl chr 7:130,342,483...130,347,587
JBrowse link
bafilomycin A1 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions EXP bafilomycin A1 inhibits the reaction [AGT protein affects the localization of Calcium] CTD PMID:21613610 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Aim2 absent in melanoma 2 multiple interactions ISO [bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of AIM2 protein CTD PMID:32645460 NCBI chr13:91,919,834...91,963,080
Ensembl chr13:91,954,138...91,962,588
JBrowse link
G Akt1s1 AKT1 substrate 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein] CTD PMID:22689575 NCBI chr 1:100,845,443...100,851,961
Ensembl chr 1:100,845,563...100,851,960
JBrowse link
G Alb albumin decreases uptake ISO bafilomycin A1 results in decreased uptake of ALB protein CTD PMID:16313995 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 increases expression ISO bafilomycin A1 results in increased expression of APAF1 protein CTD PMID:28483490 NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
JBrowse link
G Appl1 adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 multiple interactions ISO bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein] CTD PMID:25780039 NCBI chr16:2,560,103...2,602,035
Ensembl chr16:2,563,520...2,602,103
JBrowse link
G Asic1 acid sensing ion channel subunit 1 multiple interactions ISO bafilomycin A1 inhibits the reaction [Freund's Adjuvant results in increased expression of ASIC1 mRNA] CTD PMID:16769263 NCBI chr 7:141,324,714...141,354,937
Ensembl chr 7:141,326,321...141,354,937
JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]] CTD PMID:29938581 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO bafilomycin A1 inhibits the reaction [Hydroxychloroquine results in increased activity of BAX protein] CTD PMID:12813466 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO bafilomycin A1 results in decreased expression of BCL2 mRNA CTD PMID:31310755 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Becn1 beclin 1 multiple interactions ISO bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein] CTD PMID:32645460 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions ISO bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] CTD PMID:23111315 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions
increases cleavage
increases expression
EXP
ISO
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein]
vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of BID protein]
bafilomycin A1 results in increased expression of BID protein modified form
CTD PMID:26853465, PMID:28378122 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression
multiple interactions
ISO bafilomycin A1 results in increased expression of BNIP3 mRNA; bafilomycin A1 results in increased expression of BNIP3 protein
BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; vistusertib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]
CTD PMID:25981168, PMID:26853465 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G C1qtnf9 C1q and TNF related 9 multiple interactions EXP bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] CTD PMID:32278738 NCBI chr15:41,069,579...41,080,961
Ensembl chr15:41,069,507...41,081,159
JBrowse link
G Casp3 caspase 3 decreases activity
increases cleavage
multiple interactions
increases activity
ISO
EXP
bafilomycin A1 results in decreased activity of CASP3 protein
bafilomycin A1 results in increased cleavage of CASP3 protein
bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein]
bafilomycin A1 results in increased activity of CASP3 protein
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]
[bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of CASP3 protein]
CTD PMID:20876807, PMID:23380477, PMID:24321340, PMID:24889822, PMID:25266202, PMID:25981168, PMID:26853465, PMID:28063998, PMID:28378122, PMID:29111403, PMID:30240709 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp4 caspase 4 increases activity ISO bafilomycin A1 results in increased activity of CASP4 protein CTD PMID:20371669 NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
JBrowse link
G Casp7 caspase 7 increases activity
decreases activity
ISO bafilomycin A1 results in increased activity of CASP7 protein
bafilomycin A1 results in decreased activity of CASP7 protein
CTD PMID:20371669, PMID:25981168 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 multiple interactions EXP
ISO
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein]
bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein]
CTD PMID:28378122, PMID:29111403 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions EXP
ISO
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein]
bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP9 protein]
CTD PMID:28378122, PMID:30240709 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO bafilomycin A1 inhibits the reaction [xanthatin results in decreased stability of CDC25C protein] CTD PMID:29074359 NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
JBrowse link
G Ctsb cathepsin B multiple interactions ISO bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein] CTD PMID:12813466, PMID:23380477 NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions ISO bafilomycin A1 inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] CTD PMID:26682054 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Ddit4 DNA-damage-inducible transcript 4 increases expression
multiple interactions
EXP bafilomycin A1 results in increased expression of DDIT4 protein
[EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein
CTD PMID:22689575 NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
JBrowse link
G Egf epidermal growth factor multiple interactions EXP [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Aspartic Acid; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine; [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein; bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine] CTD PMID:22689575 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO bafilomycin A1 inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] CTD PMID:30237564 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein] CTD PMID:22689575 NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
JBrowse link
G Epor erythropoietin receptor multiple interactions ISO bafilomycin A1 inhibits the reaction [Aristolochic Acids results in increased degradation of and results in decreased expression of EPOR protein] CTD PMID:26136230 NCBI chr 8:22,969,737...22,974,468
Ensembl chr 8:22,969,745...22,974,321
JBrowse link
G Faslg Fas ligand multiple interactions ISO
EXP
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium]
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of FASLG protein]
CTD PMID:20200208, PMID:28378122 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fmc1 formation of mitochondrial complex V assembly factor 1 multiple interactions ISO bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein] CTD PMID:29371327 NCBI chr 4:66,276,835...66,284,868
Ensembl chr 4:66,276,835...66,284,868
JBrowse link
G Foxo1 forkhead box O1 multiple interactions EXP bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased acetylation of FOXO1 protein]] CTD PMID:24889822 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression
multiple interactions
ISO bafilomycin A1 results in increased expression of HIF1A protein
HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]
CTD PMID:25981168 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmox1 heme oxygenase 1 decreases expression
multiple interactions
ISO bafilomycin A1 results in decreased expression of HMOX1 protein
bafilomycin A1 inhibits the reaction [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in increased expression of HMOX1 protein]
CTD PMID:29796178 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Ifng interferon gamma decreases expression ISO bafilomycin A1 results in decreased expression of IFNG mRNA CTD PMID:16932910 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il1b interleukin 1 beta decreases expression
multiple interactions
ISO bafilomycin A1 results in decreased expression of IL1B mRNA
[bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]
CTD PMID:16932910, PMID:24158569, PMID:32645460 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 increases expression ISO bafilomycin A1 results in increased expression of IL6 mRNA CTD PMID:16932910 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ins2 insulin 2 multiple interactions EXP
ISO
bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein]
bafilomycin A1 promotes the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]]
CTD PMID:22689575, PMID:32283200 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Lrrk2 leucine-rich repeat kinase 2 increases response to substance ISO LRRK2 gene mutant form results in increased susceptibility to bafilomycin A1 CTD PMID:25017139 NCBI chr 7:132,857,311...133,018,549
Ensembl chr 7:132,857,628...133,018,584
JBrowse link
G Map1lc3a microtubule-associated protein 1 light chain 3 alpha multiple interactions
increases expression
ISO bafilomycin A1 promotes the reaction [Uranium results in increased expression of MAP1LC3A protein]
bafilomycin A1 results in increased expression of MAP1LC3A protein modified form
CTD PMID:30871063, PMID:31120128 NCBI chr 3:150,801,289...150,802,935
Ensembl chr 3:150,801,289...150,802,935
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions
increases lipidation
increases expression
increases cleavage
decreases degradation
ISO
EXP
[di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] results in increased expression of MAP1LC3B mRNA; [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]]; ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]]; bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein]; bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; bafilomycin A1 promotes the reaction [vistusertib results in increased expression of MAP1LC3B protein modified form]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form]
bafilomycin A1 results in increased lipidation of MAP1LC3B protein
[Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein; [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form]
bafilomycin A1 results in increased expression of MAP1LC3B protein modified form
bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein]
bafilomycin A1 results in increased cleavage of MAP1LC3B protein
bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form
bafilomycin A1 results in increased expression of MAP1LC3B protein; bafilomycin A1 results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 results in increased expression of MAP1LC3B protein modified form
CTD PMID:23880069, PMID:24145604, PMID:25301941, PMID:26459185, PMID:26853465, PMID:29248574, PMID:29524503, PMID:29908302, PMID:29938581, PMID:30209975, PMID:31310755, PMID:32278738, PMID:32525084 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases expression
ISO bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK1 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]
bafilomycin A1 results in increased expression of MAPK1 protein modified form
CTD PMID:20371669, PMID:28483490, PMID:32645460 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases expression
ISO bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK3 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]
bafilomycin A1 results in increased expression of MAPK3 protein modified form
CTD PMID:20371669, PMID:28483490, PMID:32645460 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation ISO bafilomycin A1 results in increased phosphorylation of MAPK8 protein CTD PMID:31310755 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO bafilomycin A1 results in decreased phosphorylation of MTOR protein CTD PMID:31310755 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Ndrg1 N-myc downstream regulated 1 multiple interactions ISO NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] CTD PMID:24532803 NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
increases expression
ISO bafilomycin A1 promotes the reaction [[Particulate Matter co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [[Silicon Dioxide co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Silicon Dioxide results in increased expression of NFE2L2 protein]
bafilomycin A1 results in increased expression of NFE2L2 protein
CTD PMID:30698894 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 multiple interactions
increases expression
ISO bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of NLRP3 protein]
bafilomycin A1 results in increased expression of NLRP3 protein
CTD PMID:32645460 NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 decreases expression ISO bafilomycin A1 results in decreased expression of NR5A1 protein CTD PMID:29524503 NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
increases expression
ISO bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]
bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein]
bafilomycin A1 results in increased expression of PARP1 protein modified form
CTD PMID:20876807, PMID:21616090, PMID:24321340, PMID:25981168, PMID:28063998, PMID:29111403, PMID:31310755 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO bafilomycin A1 affects the localization of and results in increased activity of RELA protein CTD PMID:10339586 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation
multiple interactions
ISO
EXP
bafilomycin A1 results in decreased phosphorylation of RPS6KB1 protein
bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein]
CTD PMID:22689575, PMID:31310755 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions ISO bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] CTD PMID:23111315 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Sirt1 sirtuin 1 multiple interactions EXP bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT1 protein]] CTD PMID:24889822 NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
JBrowse link
G Slc17a7 solute carrier family 17 member 7 multiple interactions EXP bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Excitatory Amino Acid Agents]; bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Zinc]; bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] CTD PMID:15860731 NCBI chr 1:101,161,265...101,172,292
Ensembl chr 1:101,161,252...101,173,174
JBrowse link
G Slc30a3 solute carrier family 30 member 3 multiple interactions EXP bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] CTD PMID:15860731 NCBI chr 6:26,629,752...26,650,106
Ensembl chr 6:26,642,783...26,650,105
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions
increases expression
ISO bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]
bafilomycin A1 results in increased expression of SNAI1 protein
CTD PMID:32645460 NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
JBrowse link
G Snca synuclein alpha multiple interactions
increases expression
ISO [bafilomycin A1 co-treated with Rotenone] results in increased expression of SNCA protein
bafilomycin A1 results in increased expression of SNCA protein
CTD PMID:26031332 NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
JBrowse link
G Sort1 sortilin 1 decreases expression ISO bafilomycin A1 results in decreased expression of SORT1 protein CTD PMID:25805502 NCBI chr 2:211,078,092...211,156,312
Ensembl chr 2:211,078,334...211,156,312
JBrowse link
G Sqstm1 sequestosome 1 increases expression
multiple interactions
ISO
EXP
bafilomycin A1 results in increased expression of SQSTM1 protein
bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein]
[Resveratrol co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; sodium arsenite promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Resveratrol inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; Streptozocin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]
CTD PMID:21778691, PMID:21858812, PMID:23151917, PMID:24145604, PMID:24238063, PMID:24889822, PMID:25939952, PMID:25943029, PMID:26031332, PMID:28125038, PMID:29248574, PMID:29524503, PMID:30698894, PMID:32186374, PMID:32645460 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Tbk1 TANK-binding kinase 1 multiple interactions ISO bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] CTD PMID:25780039 NCBI chr 7:63,655,247...63,687,978
Ensembl chr 7:63,655,247...63,687,978
JBrowse link
G Tlr8 toll-like receptor 8 multiple interactions ISO bafilomycin A1 inhibits the reaction [resiquimod results in increased activity of TLR8 protein] CTD PMID:21398612 NCBI chr  X:28,539,158...28,562,803
Ensembl chr  X:28,539,158...28,562,803
JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions
ISO bafilomycin A1 results in increased expression of TNF mRNA
[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form]
CTD PMID:16932910, PMID:24145604 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tomm20 translocase of outer mitochondrial membrane 20 increases expression
multiple interactions
ISO bafilomycin A1 results in increased expression of TOMM20 protein
Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein]
CTD PMID:30209975 NCBI chr19:59,863,421...59,873,411
Ensembl chr19:59,863,421...59,873,411
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] CTD PMID:23380477 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Ulk1 unc-51 like autophagy activating kinase 1 multiple interactions EXP bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]] CTD PMID:29128638 NCBI chr12:51,908,105...51,934,704
Ensembl chr12:51,908,448...51,934,702
JBrowse link
G Vdac1 voltage-dependent anion channel 1 multiple interactions
increases expression
ISO Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] CTD PMID:30209975 NCBI chr10:37,724,915...37,752,827
Ensembl chr10:37,724,915...37,752,826
JBrowse link
G Vdr vitamin D receptor multiple interactions ISO [bafilomycin A1 co-treated with Vitamin D] results in increased expression of VDR protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of VDR protein CTD PMID:30698894 NCBI chr 7:139,344,452...139,394,138
Ensembl chr 7:139,342,063...139,394,166
JBrowse link
G Vim vimentin multiple interactions
increases expression
ISO bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]
bafilomycin A1 results in increased expression of VIM protein
CTD PMID:32645460 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
Epomediol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp7a1 cytochrome P450 family 7 subfamily A member 1 increases activity
increases expression
EXP epomediol results in increased activity of CYP7A1 protein
epomediol results in increased expression of CYP7A1 mRNA
CTD PMID:10961725, PMID:11473529 NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions EXP [Ethinyl Estradiol co-treated with epomediol] results in increased activity of GCLM protein CTD PMID:12071332 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
JBrowse link
G Ggt1 gamma-glutamyltransferase 1 multiple interactions EXP [Ethinyl Estradiol co-treated with epomediol] results in increased activity of GGT1 protein CTD PMID:12071332 NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase increases activity EXP epomediol results in increased activity of HMGCR protein CTD PMID:10961725, PMID:11473529 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
Heptachlor epoxide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of ABCA1 mRNA CTD PMID:25270620 NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Heptachlor Epoxide results in increased expression of ABCC2 mRNA CTD PMID:25270620 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Abcg1 ATP binding cassette subfamily G member 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of ABCG1 mRNA CTD PMID:25270620 NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
JBrowse link
G Abhd17c abhydrolase domain containing 17C, depalmitoylase decreases expression ISO Heptachlor Epoxide results in decreased expression of ABHD17C mRNA CTD PMID:25270620 NCBI chr 1:146,248,505...146,289,465
Ensembl chr 1:146,248,503...146,289,465
JBrowse link
G Acp5 acid phosphatase 5, tartrate resistant increases expression ISO Heptachlor Epoxide results in increased expression of ACP5 mRNA CTD PMID:25270620 NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396
JBrowse link
G Adgre5 adhesion G protein-coupled receptor E5 increases expression ISO Heptachlor Epoxide results in increased expression of ADGRE5 mRNA CTD PMID:25270620 NCBI chr19:24,854,981...24,875,712
Ensembl chr19:24,855,299...24,875,137
JBrowse link
G Agtr1a angiotensin II receptor, type 1a decreases expression ISO Heptachlor Epoxide results in decreased expression of AGTR1A mRNA CTD PMID:25270620 NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
JBrowse link
G Ammecr1l AMMECR1 like increases expression ISO Heptachlor Epoxide results in increased expression of AMMECR1L mRNA CTD PMID:25270620 NCBI chr18:24,539,530...24,563,576
Ensembl chr18:24,540,659...24,563,576
JBrowse link
G Ankrd44 ankyrin repeat domain 44 increases expression ISO Heptachlor Epoxide results in increased expression of ANKRD44 mRNA CTD PMID:25270620 NCBI chr 9:61,229,252...61,529,532
Ensembl chr 9:61,231,988...61,528,882
JBrowse link
G Aplp1 amyloid beta precursor like protein 1 increases expression ISO Heptachlor Epoxide results in increased expression of APLP1 mRNA CTD PMID:25270620 NCBI chr 1:88,897,525...88,908,750
Ensembl chr 1:88,897,532...88,908,750
JBrowse link
G Ar androgen receptor multiple interactions ISO Dihydrotestosterone inhibits the reaction [Heptachlor Epoxide results in increased activity of AR protein] CTD PMID:15064155 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Atl3 atlastin GTPase 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of ATL3 mRNA CTD PMID:25270620 NCBI chr 1:222,746,023...222,788,439
Ensembl chr 1:222,746,023...222,786,942
JBrowse link
G Atp9a ATPase phospholipid transporting 9A (putative) decreases expression ISO Heptachlor Epoxide results in decreased expression of ATP9A mRNA CTD PMID:25270620 NCBI chr 3:165,405,588...165,511,104
Ensembl chr 3:165,412,803...165,477,771
JBrowse link
G Bhlhe40 basic helix-loop-helix family, member e40 increases expression ISO Heptachlor Epoxide results in increased expression of BHLHE40 mRNA CTD PMID:25270620 NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
JBrowse link
G Camk2n1 calcium/calmodulin-dependent protein kinase II inhibitor 1 increases expression ISO Heptachlor Epoxide results in increased expression of CAMK2N1 mRNA CTD PMID:25270620 NCBI chr 5:156,876,706...156,878,486
Ensembl chr 5:156,876,706...156,878,486
JBrowse link
G Cnot7 CCR4-NOT transcription complex, subunit 7 increases expression ISO Heptachlor Epoxide results in increased expression of CNOT7 mRNA CTD PMID:25270620 NCBI chr16:54,899,452...54,918,616
Ensembl chr16:54,899,452...54,918,613
JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A decreases expression ISO Heptachlor Epoxide results in decreased expression of CPT1A mRNA CTD PMID:25270620 NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity ISO Heptachlor Epoxide results in decreased activity of CYP1A1 protein CTD PMID:15620088 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp26a1 cytochrome P450, family 26, subfamily a, polypeptide 1 increases expression ISO Heptachlor Epoxide results in increased expression of CYP26A1 mRNA CTD PMID:25270620 NCBI chr 1:256,382,861...256,386,729
Ensembl chr 1:256,382,791...256,386,729
JBrowse link
G Cyp2c24 cytochrome P450, family 2, subfamily c, polypeptide 24 increases expression ISO Heptachlor Epoxide results in increased expression of CYP2C55 mRNA CTD PMID:25270620 NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases expression ISO Heptachlor Epoxide results in increased expression of CYP2C29 mRNA CTD PMID:25270620 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Dpp4 dipeptidylpeptidase 4 increases expression ISO Heptachlor Epoxide results in increased expression of DPP4 mRNA CTD PMID:25270620 NCBI chr 3:48,291,055...48,372,672
Ensembl chr 3:48,291,055...48,372,672
JBrowse link
G Dppa3 developmental pluripotency-associated 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of DPPA3 mRNA CTD PMID:25270620 NCBI chr 4:155,437,675...155,441,059
Ensembl chr 3:111,298,713...111,299,189
Ensembl chr 4:111,298,713...111,299,189
JBrowse link
G Ecscr endothelial cell surface expressed chemotaxis and apoptosis regulator decreases expression ISO Heptachlor Epoxide results in decreased expression of ECSCR mRNA CTD PMID:25270620 NCBI chr18:28,507,167...28,516,567
Ensembl chr18:28,506,934...28,516,209
JBrowse link
G Efna1 ephrin A1 increases expression ISO Heptachlor Epoxide results in increased expression of EFNA1 mRNA CTD PMID:25270620 NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
JBrowse link
G Elovl6 ELOVL fatty acid elongase 6 increases expression ISO Heptachlor Epoxide results in increased expression of ELOVL6 mRNA CTD PMID:25270620 NCBI chr 2:234,187,490...234,296,124
Ensembl chr 2:234,189,105...234,296,145
Ensembl chr 2:234,189,105...234,296,145
JBrowse link
G Ephb4 EPH receptor B4 decreases expression ISO Heptachlor Epoxide results in decreased expression of EPHB4 mRNA CTD PMID:25270620 NCBI chr12:22,393,338...22,418,332
Ensembl chr12:22,393,330...22,417,980
JBrowse link
G Ephx1 epoxide hydrolase 1 multiple interactions ISO Heptachlor Epoxide promotes the reaction [EPHX1 protein results in increased metabolism of stilbene oxide] CTD PMID:2043152 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Ephx2 epoxide hydrolase 2 multiple interactions ISO Heptachlor Epoxide inhibits the reaction [EPHX2 protein results in increased metabolism of stilbene oxide analog]; Heptachlor Epoxide promotes the reaction [EPHX2 protein results in increased metabolism of stilbene oxide] CTD PMID:2043152 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 increases activity ISO Heptachlor Epoxide results in increased activity of ERBB2 protein CTD PMID:11222871 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Esr1 estrogen receptor 1 increases activity ISO Heptachlor Epoxide results in increased activity of ESR1 protein CTD PMID:15064155 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 increases activity ISO Heptachlor Epoxide results in increased activity of ESR2 protein CTD PMID:15064155 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G Exosc8 exosome component 8 increases expression ISO Heptachlor Epoxide results in increased expression of EXOSC8 mRNA CTD PMID:25270620 NCBI chr 2:143,925,643...143,932,240
Ensembl chr 2:143,925,546...143,931,940
JBrowse link
G Faah fatty acid amide hydrolase decreases expression ISO Heptachlor Epoxide results in decreased expression of FAAH mRNA CTD PMID:25270620 NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
JBrowse link
G Faahl fatty-acid amide hydrolase-like decreases expression ISO Heptachlor Epoxide results in decreased expression of FAAH mRNA CTD PMID:25270620 NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
JBrowse link
G Fgf21 fibroblast growth factor 21 decreases expression ISO Heptachlor Epoxide results in decreased expression of FGF21 mRNA CTD PMID:25270620 NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
JBrowse link
G Fmo1 flavin containing dimethylaniline monoxygenase 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of FMO1 mRNA CTD PMID:25270620 NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
JBrowse link
G Gabarapl2 GABA type A receptor associated protein like 2 increases expression ISO Heptachlor Epoxide results in increased expression of GABARAPL2 mRNA CTD PMID:25270620 NCBI chr19:44,164,935...44,175,771
Ensembl chr19:44,164,935...44,175,770
JBrowse link
G Gja1 gap junction protein, alpha 1 decreases phosphorylation
decreases expression
multiple interactions
EXP
ISO
Heptachlor Epoxide results in decreased phosphorylation of GJA1 protein
Heptachlor Epoxide results in decreased expression of GJA1 protein
Heptachlor Epoxide results in decreased expression of and results in decreased phosphorylation of GJA1 protein
Heptachlor Epoxide results in decreased expression of GJA1 mRNA
CTD PMID:8068183, PMID:8738476, PMID:11246134 NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
JBrowse link
G Gjb2 gap junction protein, beta 2 decreases expression EXP Heptachlor Epoxide results in decreased expression of GJB2 protein CTD PMID:8068183 NCBI chr15:37,377,313...37,394,494
Ensembl chr15:37,377,316...37,383,277
JBrowse link
G Gjb3 gap junction protein, beta 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of GJB3 mRNA CTD PMID:25270620 NCBI chr 5:145,390,590...145,397,271
Ensembl chr 5:145,391,311...145,392,123
JBrowse link
G Gsr glutathione-disulfide reductase affects activity ISO Heptachlor Epoxide affects the activity of GSR protein CTD PMID:15620088 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Hagh hydroxyacyl glutathione hydrolase increases expression ISO Heptachlor Epoxide results in increased expression of HAGH mRNA CTD PMID:25270620 NCBI chr10:14,215,913...14,230,506
Ensembl chr10:14,216,155...14,230,515
JBrowse link
G Hbegf heparin-binding EGF-like growth factor increases expression ISO Heptachlor Epoxide results in increased expression of HBEGF mRNA CTD PMID:25270620 NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase increases expression ISO Heptachlor Epoxide results in increased expression of HMGCR mRNA CTD PMID:25270620 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of HMGCS2 mRNA CTD PMID:25270620 NCBI chr 2:200,452,623...200,480,785
Ensembl chr 2:200,452,624...200,479,423
JBrowse link
G Hsd3b3 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of HSD3B3 mRNA CTD PMID:25270620 NCBI chr 2:200,756,557...200,762,492
Ensembl chr 2:200,585,748...200,762,492
JBrowse link
G Hyal1 hyaluronidase 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of HYAL1 mRNA CTD PMID:25270620 NCBI chr 8:116,332,834...116,337,522
Ensembl chr 8:116,332,796...116,335,435
JBrowse link
G Inhbb inhibin subunit beta B increases expression ISO Heptachlor Epoxide results in increased expression of INHBB mRNA CTD PMID:25270620 NCBI chr13:35,436,532...35,442,222
Ensembl chr13:35,436,532...35,442,222
JBrowse link
G Insm1 INSM transcriptional repressor 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of INSM1 mRNA CTD PMID:25270620 NCBI chr 3:140,427,961...140,430,467 JBrowse link
G Itpr3 inositol 1,4,5-trisphosphate receptor, type 3 increases expression ISO Heptachlor Epoxide results in increased expression of ITPR3 mRNA CTD PMID:25270620 NCBI chr20:5,645,894...5,711,702
Ensembl chr20:5,646,097...5,711,702
JBrowse link
G Jmjd6 jumonji domain containing 6, arginine demethylase and lysine hydroxylase increases expression ISO Heptachlor Epoxide results in increased expression of JMJD6 mRNA CTD PMID:25270620 NCBI chr10:105,781,752...105,787,803
Ensembl chr10:105,781,753...105,787,803
JBrowse link
G Klf12 Kruppel-like factor 12 decreases expression ISO Heptachlor Epoxide results in decreased expression of KLF12 mRNA CTD PMID:25270620 NCBI chr15:84,316,986...84,748,549
Ensembl chr15:84,324,470...84,748,525
JBrowse link
G Llgl2 LLGL scribble cell polarity complex component 2 increases expression ISO Heptachlor Epoxide results in increased expression of LLGL2 mRNA CTD PMID:25270620 NCBI chr10:104,367,826...104,403,726
Ensembl chr10:104,368,247...104,403,724
JBrowse link
G Lnx2 ligand of numb-protein X 2 increases expression ISO Heptachlor Epoxide results in increased expression of LNX2 mRNA CTD PMID:25270620 NCBI chr12:9,728,415...9,793,428
Ensembl chr12:9,728,486...9,793,428
JBrowse link
G Lpl lipoprotein lipase decreases expression ISO Heptachlor Epoxide results in decreased expression of LPL mRNA CTD PMID:25270620 NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
JBrowse link
G Mcam melanoma cell adhesion molecule decreases expression ISO Heptachlor Epoxide results in decreased expression of MCAM mRNA CTD PMID:25270620 NCBI chr 8:48,472,824...48,481,005
Ensembl chr 8:48,472,824...48,481,001
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression ISO Heptachlor Epoxide results in increased expression of MCL1 mRNA CTD PMID:25270620 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mn1 MN1 proto-oncogene, transcriptional regulator decreases expression ISO Heptachlor Epoxide results in decreased expression of MN1 mRNA CTD PMID:25270620 NCBI chr12:51,214,192...51,250,230
Ensembl chr12:51,214,192...51,250,230
JBrowse link
G Mpeg1 macrophage expressed 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of MPEG1 mRNA CTD PMID:25270620 NCBI chr 1:228,724,559...228,729,054
Ensembl chr 1:228,724,900...228,727,160
JBrowse link
G Msmo1 methylsterol monooxygenase 1 increases expression ISO Heptachlor Epoxide results in increased expression of MSMO1 mRNA CTD PMID:25270620 NCBI chr16:26,859,441...26,875,880
Ensembl chr16:26,859,397...26,875,973
JBrowse link
G Mtarc2 mitochondrial amidoxime reducing component 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of MTARC2 mRNA CTD PMID:25270620 NCBI chr13:102,724,266...102,755,511
Ensembl chr13:102,724,348...102,756,174
JBrowse link
G Mycn MYCN proto-oncogene, bHLH transcription factor decreases expression ISO Heptachlor Epoxide results in decreased expression of MYCN mRNA CTD PMID:25270620 NCBI chr 6:38,222,554...38,228,419
Ensembl chr 6:38,222,555...38,228,379
JBrowse link
G Mylip myosin regulatory light chain interacting protein decreases expression ISO Heptachlor Epoxide results in decreased expression of MYLIP mRNA CTD PMID:25270620 NCBI chr17:19,682,040...19,703,681
Ensembl chr17:19,682,040...19,703,681
JBrowse link
G Myo1f myosin IF increases expression ISO Heptachlor Epoxide results in increased expression of MYO1F mRNA CTD PMID:25270620 NCBI chr 7:18,440,742...18,491,448
Ensembl chr 7:18,440,742...18,491,448
JBrowse link
G Ndrg1 N-myc downstream regulated 1 increases expression ISO Heptachlor Epoxide results in increased expression of NDRG1 mRNA CTD PMID:25270620 NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
JBrowse link
G Nefl neurofilament light decreases expression ISO Heptachlor Epoxide results in decreased expression of NEFL mRNA CTD PMID:25270620 NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
JBrowse link
G Nnt nicotinamide nucleotide transhydrogenase decreases expression ISO Heptachlor Epoxide results in decreased expression of NNT mRNA CTD PMID:25270620 NCBI chr 2:52,189,523...52,283,095
Ensembl chr 2:52,189,529...52,282,548
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO Heptachlor Epoxide binds to and results in increased activity of NR1I2 protein CTD PMID:21115097 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 increases activity ISO Heptachlor Epoxide results in increased activity of NR1I3 protein CTD PMID:28927721 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Orc2 origin recognition complex, subunit 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of ORC2 mRNA CTD PMID:25270620 NCBI chr 9:65,350,630...65,387,293
Ensembl chr 9:65,350,627...65,387,169
JBrowse link
G Peg3 paternally expressed 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of PEG3 mRNA CTD PMID:25270620 NCBI chr 1:70,210,810...70,237,450
Ensembl chr 1:70,222,964...70,237,443
JBrowse link
G Pfkfb1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of PFKFB1 mRNA CTD PMID:25270620 NCBI chr  X:23,092,143...23,145,923
Ensembl chr  X:23,092,159...23,144,324
JBrowse link
G Pgr progesterone receptor multiple interactions
increases expression
ISO ICI 164384 inhibits the reaction [Heptachlor Epoxide results in increased expression of PGR mRNA] CTD PMID:16242299 NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
JBrowse link
G Phlda3 pleckstrin homology-like domain, family A, member 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of PHLDA3 mRNA CTD PMID:25270620 NCBI chr13:52,588,917...52,592,002
Ensembl chr13:52,588,917...52,592,001
JBrowse link
G Pla2g12a phospholipase A2, group XIIA increases expression ISO Heptachlor Epoxide results in increased expression of PLA2G12A mRNA CTD PMID:25270620 NCBI chr 2:235,311,664...235,327,972
Ensembl chr 2:235,311,719...235,327,972
JBrowse link
G Plcg1 phospholipase C, gamma 1 increases expression ISO Heptachlor Epoxide results in increased expression of PLCG1 protein CTD PMID:11246134 NCBI chr 3:156,727,642...156,758,307
Ensembl chr 3:156,727,642...156,758,307
JBrowse link
G Plekha5 pleckstrin homology domain containing A5 increases expression ISO Heptachlor Epoxide results in increased expression of PLEKHA5 mRNA CTD PMID:25270620 NCBI chr 4:174,605,462...174,774,692
Ensembl chr 4:174,605,476...174,774,693
JBrowse link
G Porcn porcupine O-acyltransferase increases expression ISO Heptachlor Epoxide results in increased expression of PORCN mRNA CTD PMID:25270620 NCBI chr  X:15,035,569...15,048,440
Ensembl chr  X:15,035,569...15,048,440
JBrowse link
G Prkce protein kinase C, epsilon increases expression
decreases expression
ISO Heptachlor Epoxide results in increased expression of PRKCE protein alternative form
Heptachlor Epoxide results in decreased expression of PRKCE protein alternative form
CTD PMID:11170310, PMID:11246134 NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
JBrowse link
G Psmg3 proteasome assembly chaperone 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of PSMG3 mRNA CTD PMID:25270620 NCBI chr12:16,898,999...16,901,945
Ensembl chr12:16,899,025...16,901,934
JBrowse link
G Ptcd1 pentatricopeptide repeat domain 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of PTCD1 mRNA CTD PMID:25270620 NCBI chr12:11,215,795...11,233,633
Ensembl chr12:11,215,886...11,233,633
JBrowse link
G Ptges prostaglandin E synthase increases expression ISO Heptachlor Epoxide results in increased expression of PTGES mRNA CTD PMID:25270620 NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
JBrowse link
G Rdh11 retinol dehydrogenase 11 increases expression ISO Heptachlor Epoxide results in increased expression of RDH11 mRNA CTD PMID:25270620 NCBI chr 6:102,356,498...102,372,618
Ensembl chr 6:102,356,492...102,372,611
JBrowse link
G Rnf145 ring finger protein 145 decreases expression ISO Heptachlor Epoxide results in decreased expression of RNF145 mRNA CTD PMID:25270620 NCBI chr10:30,169,147...30,207,505
Ensembl chr10:30,169,257...30,207,498
JBrowse link
G Scd stearoyl-CoA desaturase decreases expression ISO Heptachlor Epoxide results in decreased expression of SCD1 mRNA CTD PMID:25270620 NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
JBrowse link
G Scd2 stearoyl-Coenzyme A desaturase 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of SCD2 mRNA CTD PMID:25270620 NCBI chr 1:264,059,374...264,072,433
Ensembl chr 1:264,059,374...264,072,433
JBrowse link
G Sdc2 syndecan 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of SDC2 mRNA CTD PMID:25270620 NCBI chr 7:71,572,731...71,686,139
Ensembl chr 7:71,572,941...71,686,044
JBrowse link
G Slc16a2 solute carrier family 16 member 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of SLC16A2 mRNA CTD PMID:25270620 NCBI chr  X:74,578,600...74,706,068
Ensembl chr  X:74,577,131...74,706,214
JBrowse link
G Slc18a2 solute carrier family 18 member A2 multiple interactions ISO Heptachlor Epoxide inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine] CTD PMID:10499361 NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
JBrowse link
G Slc25a51 solute carrier family 25, member 51 increases expression ISO Heptachlor Epoxide results in increased expression of SLC25A51 mRNA CTD PMID:25270620 NCBI chr 5:61,120,419...61,130,053
Ensembl chr 5:61,120,419...61,130,026
JBrowse link
G Slc3a2 solute carrier family 3 member 2 increases expression ISO Heptachlor Epoxide results in increased expression of SLC3A2 mRNA CTD PMID:25270620 NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
JBrowse link
G Sntb2 syntrophin, beta 2 increases expression ISO Heptachlor Epoxide results in increased expression of SNTB2 mRNA CTD PMID:25270620 NCBI chr19:39,126,589...39,209,152
Ensembl chr19:39,126,589...39,209,152
JBrowse link
G Sqor sulfide quinone oxidoreductase decreases expression ISO Heptachlor Epoxide results in decreased expression of SQOR mRNA CTD PMID:25270620 NCBI chr 3:114,894,944...114,939,375
Ensembl chr 3:114,900,343...114,939,370
JBrowse link
G Srsf2 serine and arginine rich splicing factor 2 decreases expression ISO Heptachlor Epoxide results in decreased expression of SRSF2 mRNA CTD PMID:25270620 NCBI chr10:105,792,779...105,795,986
Ensembl chr10:105,792,779...105,795,958
JBrowse link
G Srsf9 serine and arginine rich splicing factor 9 decreases expression ISO Heptachlor Epoxide results in decreased expression of SRSF9 mRNA CTD PMID:25270620 NCBI chr12:47,039,714...47,046,022
Ensembl chr12:47,039,716...47,046,022
JBrowse link
G Steap1 STEAP family member 1 increases expression ISO Heptachlor Epoxide results in increased expression of STEAP1 mRNA CTD PMID:25270620 NCBI chr 4:25,435,885...25,446,393
Ensembl chr 4:25,435,873...25,446,461
JBrowse link
G Steap2 STEAP2 metalloreductase increases expression ISO Heptachlor Epoxide results in increased expression of STEAP2 mRNA CTD PMID:25270620 NCBI chr 4:25,506,604...25,527,088
Ensembl chr 4:25,507,463...25,527,087
JBrowse link
G Stra8 stimulated by retinoic acid 8 increases expression ISO Heptachlor Epoxide results in increased expression of STRA8 mRNA CTD PMID:25270620 NCBI chr 4:62,447,724...62,474,802
Ensembl chr 4:62,457,694...62,473,360
JBrowse link
G Tamalin trafficking regulator and scaffold protein tamalin increases expression ISO Heptachlor Epoxide results in increased expression of GRASP mRNA CTD PMID:25270620 NCBI chr 7:142,869,785...142,877,551
Ensembl chr 7:142,869,752...142,878,347
JBrowse link
G Tceal8 transcription elongation factor A like 8 decreases expression ISO Heptachlor Epoxide results in decreased expression of TCEAL8 mRNA CTD PMID:25270620 NCBI chr  X:106,713,319...106,715,391
Ensembl chr  X:106,713,320...106,715,391
JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase decreases expression ISO Heptachlor Epoxide results in decreased expression of TDO2 mRNA CTD PMID:25270620 NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
JBrowse link
G Tefm transcription elongation factor, mitochondrial increases expression ISO Heptachlor Epoxide results in increased expression of TEFM mRNA CTD PMID:25270620 NCBI chr10:67,476,006...67,478,830
Ensembl chr10:67,475,968...67,479,077
JBrowse link
G Tff1 trefoil factor 1 increases expression
multiple interactions
ISO Heptachlor Epoxide results in increased expression of TFF1 mRNA
ICI 164384 inhibits the reaction [Heptachlor Epoxide results in increased expression of TFF1 mRNA]
CTD PMID:16242299 NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
JBrowse link
G Tmem254 transmembrane protein 254 decreases expression ISO Heptachlor Epoxide results in decreased expression of TMEM254A mRNA CTD PMID:25270620 NCBI chr16:3,817,402...3,821,270
Ensembl chr16:3,817,402...3,821,270
JBrowse link
G Tnfaip3 TNF alpha induced protein 3 decreases expression ISO Heptachlor Epoxide results in decreased expression of TNFAIP3 mRNA CTD PMID:25270620 NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
JBrowse link
G Tns1 tensin 1 decreases expression ISO Heptachlor Epoxide results in decreased expression of TNS1 mRNA CTD PMID:25270620 NCBI chr 9:81,190,192...81,401,020
Ensembl chr 9:81,194,119...81,400,987
JBrowse link
G Tspo translocator protein increases expression EXP Heptachlor Epoxide results in increased expression of TSPO CTD PMID:14699885 NCBI chr 7:124,460,358...124,470,610
Ensembl chr 7:124,460,358...124,470,609
JBrowse link
G Ttc39b tetratricopeptide repeat domain 39B increases expression ISO Heptachlor Epoxide results in increased expression of TTC39B mRNA CTD PMID:25270620 NCBI chr 5:101,304,982...101,405,689
Ensembl chr 5:101,304,982...101,405,656
JBrowse link
G Usp14 ubiquitin specific peptidase 14 increases expression ISO Heptachlor Epoxide results in increased expression of USP14 mRNA CTD PMID:25270620 NCBI chr18:1,178,785...1,216,573
Ensembl chr18:1,178,787...1,216,409
JBrowse link
G Zmym3 zinc finger MYM-type containing 3 increases expression ISO Heptachlor Epoxide results in increased expression of ZMYM3 mRNA CTD PMID:25270620 NCBI chr  X:71,298,737...71,313,529
Ensembl chr  X:71,299,662...71,313,542
JBrowse link
lasalocid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mapt microtubule-associated protein tau decreases expression ISO Lasalocid results in decreased expression of MAPT protein CTD PMID:16930453 NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
JBrowse link
venetoclax term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator decreases activity ISO venetoclax results in decreased activity of BCL2 protein CTD PMID:26214592 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [YM 155 co-treated with venetoclax] results in decreased expression of BIRC5 protein CTD PMID:31837377 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP3 protein CTD PMID:31837377 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp9 caspase 9 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of CASP9 protein CTD PMID:31837377 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member increases expression
multiple interactions
ISO venetoclax results in increased expression of MCL1 protein
[YM 155 co-treated with venetoclax] results in decreased expression of MCL1 protein
CTD PMID:31837377 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [venetoclax co-treated with YM 155] results in increased cleavage of PARP1 protein CTD PMID:31837377 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    chemical entity 19785
      atom 19782
        nonmetal atom 19657
          oxygen atom 19321
            oxygen molecular entity 19321
              organooxygen compound 18777
                oxacycle 17181
                  oxanes 198
                    (2-formyloxan-3-yl) acetate 0
                    (3R,6aR,8R,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3R,6aR,8S,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3R,6aS,8R,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-1,2-oxazol-4-yl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3R,6aS,8S,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3S,6aR,8R,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3S,6aR,8S,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3S,6aS,8R,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    (3S,6aS,8S,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                    2-[(3R,6aR,8R,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3R,6aR,8R,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                    2-[(3R,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3R,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                    2-[(3R,6aS,8R,10aS)-1-(cyclopentanecarbonyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3R,6aS,8R,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(oxane-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-benzylacetamide 0
                    2-[(3R,6aS,8S,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclopentylacetamide 0
                    2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                    2-[(3S,6aR,8R,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-methylacetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3S,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3S,6aR,8S,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3S,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(oxane-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3S,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3S,6aS,8R,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3S,6aS,8R,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(propylcarbamoyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                    2-[(3S,6aS,8S,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                    2-[(3S,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                    2-[(3S,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                    2-chloro-N-[2-(2,2-dimethyl-4-phenyl-4-oxanyl)ethyl]acetamide 0
                    3-imino-1,5,5-trimethyl-2-oxabicyclo[2.2.1]heptane-4,7,7-tricarbonitrile 0
                    Abyssomicin I 0
                    Aurothioglucose 17
                    Avermectin A2a aglycone 0
                    Avermectin A2b aglycone 0
                    Avermectin B2b aglycone 0
                    Bis(2,3-epoxycyclopentyl)ether 0
                    Bisabolol oxide A 0
                    Caespitol 0
                    Chlorochrymorin 0
                    Coronarian 0
                    Cunaniol 0
                    Cytosporin D 0
                    Daucol 0
                    Epomediol 4
                    Heptachlor epoxide 110
                    Hymenoxon 0
                    Ichthyotherol 0
                    Isocaespitol 0
                    Linalool oxide pyranoside 0
                    Microhelenin A 0
                    N-(4-\{4-amino-1-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl\}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide 0
                    N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-carboxamide 0
                    N-[2-morpholin-4-yl-1-(morpholin-4-ylmethyl)ethyl]-3-nitro-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide 0
                    N-\{3-[4-(3-aminopropyl)piperazin-1-yl]propyl\}-3-(2-thiophen-2-ylacetylamino)-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide 0
                    N-tert-butyl-7,7-dimethyl-2-oxo-1,8-dioxaspiro[4.5]decane-4-carboxamide 0
                    Oxychlordane 0
                    PF-4800567 0
                    Plaunol D 0
                    Smardaesidin C, (rel)- 0
                    Tepraloxydim 0
                    Tetrahydro-2,5-dimethyl-2H-pyranmethanol 0
                    Tritoniopsin A, rel- 0
                    Tritoniopsin B, rel- 0
                    Tritoniopsin C, rel- 0
                    Tritoniopsin D 0
                    \{(2R,3S,4S,5S)-3,4-dihydroxy-5-(hydroxymethyl)-5-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methoxytetrahydro-2H-pyran-2-yloxy]tetrahydrofuran-2-yl\}methyl nonanoate 0
                    auricin 0
                    bafilomycin A1 68
                    daibuoxide 0
                    gilteritinib 0
                    hygrolidin 0
                    indanomycin 0
                    lasalocid 1
                    linaloyl oxide 0
                    marinolic acid C 0
                    methyl 2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                    methyl 2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                    methyl 2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                    mupirocin 0
                    myriaporone 3 0
                    oxane + 0
                    pederin 0
                    rose oxide + 0
                    venetoclax 6
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic molecule 19486
                              organic cyclic compound 19282
                                organic heterocyclic compound 18407
                                  organic heteromonocyclic compound 16444
                                    oxanes 198
                                      (2-formyloxan-3-yl) acetate 0
                                      (3R,6aR,8R,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3R,6aR,8S,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3R,6aS,8R,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-1,2-oxazol-4-yl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3R,6aS,8S,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3S,6aR,8R,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3S,6aR,8S,10aR)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3S,6aS,8R,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      (3S,6aS,8S,10aS)-8-[2-(cyclopropylmethylamino)-2-oxoethyl]-N-(3,5-dimethyl-4-isoxazolyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide 0
                                      2-[(3R,6aR,8R,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3R,6aR,8R,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                                      2-[(3R,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3R,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                                      2-[(3R,6aS,8R,10aS)-1-(cyclopentanecarbonyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3R,6aS,8R,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(oxane-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-benzylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3R,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[(1S)-1-phenylethyl]acetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclopentylacetamide 0
                                      2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                                      2-[(3S,6aR,8R,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(1-oxopropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-methylacetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3S,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3S,6aR,8S,10aR)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3S,6aR,8S,10aR)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(oxane-4-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3S,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3S,6aS,8R,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3S,6aS,8R,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(propylcarbamoyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methylsulfonyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(phenylmethyl)acetamide 0
                                      2-[(3S,6aS,8S,10aS)-1-(cyclopentylmethyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-[3-(dimethylamino)propyl]acetamide 0
                                      2-[(3S,6aS,8S,10aS)-1-[cyclopentyl(oxo)methyl]-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N,N-dimethylacetamide 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid methyl ester 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(4-oxanylmethyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclopropylmethyl)acetamide 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[4-oxanyl(oxo)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-ethylacetamide 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(propylamino)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetic acid 0
                                      2-[(3S,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide 0
                                      2-chloro-N-[2-(2,2-dimethyl-4-phenyl-4-oxanyl)ethyl]acetamide 0
                                      3-imino-1,5,5-trimethyl-2-oxabicyclo[2.2.1]heptane-4,7,7-tricarbonitrile 0
                                      Abyssomicin I 0
                                      Aurothioglucose 17
                                      Avermectin A2a aglycone 0
                                      Avermectin A2b aglycone 0
                                      Avermectin B2b aglycone 0
                                      Bis(2,3-epoxycyclopentyl)ether 0
                                      Bisabolol oxide A 0
                                      Caespitol 0
                                      Chlorochrymorin 0
                                      Coronarian 0
                                      Cunaniol 0
                                      Cytosporin D 0
                                      Daucol 0
                                      Epomediol 4
                                      Heptachlor epoxide 110
                                      Hymenoxon 0
                                      Ichthyotherol 0
                                      Isocaespitol 0
                                      Linalool oxide pyranoside 0
                                      Microhelenin A 0
                                      N-(4-\{4-amino-1-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl\}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide 0
                                      N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)tetrahydro-2H-pyran-4-carboxamide 0
                                      N-[2-morpholin-4-yl-1-(morpholin-4-ylmethyl)ethyl]-3-nitro-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide 0
                                      N-\{3-[4-(3-aminopropyl)piperazin-1-yl]propyl\}-3-(2-thiophen-2-ylacetylamino)-5-(3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)benzamide 0
                                      N-tert-butyl-7,7-dimethyl-2-oxo-1,8-dioxaspiro[4.5]decane-4-carboxamide 0
                                      Oxychlordane 0
                                      PF-4800567 0
                                      Plaunol D 0
                                      Smardaesidin C, (rel)- 0
                                      Tepraloxydim 0
                                      Tetrahydro-2,5-dimethyl-2H-pyranmethanol 0
                                      Tritoniopsin A, rel- 0
                                      Tritoniopsin B, rel- 0
                                      Tritoniopsin C, rel- 0
                                      Tritoniopsin D 0
                                      \{(2R,3S,4S,5S)-3,4-dihydroxy-5-(hydroxymethyl)-5-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-methoxytetrahydro-2H-pyran-2-yloxy]tetrahydrofuran-2-yl\}methyl nonanoate 0
                                      auricin 0
                                      bafilomycin A1 68
                                      daibuoxide 0
                                      gilteritinib 0
                                      hygrolidin 0
                                      indanomycin 0
                                      lasalocid 1
                                      linaloyl oxide 0
                                      marinolic acid C 0
                                      methyl 2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                                      methyl 2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                                      methyl 2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]acetate 0
                                      mupirocin 0
                                      myriaporone 3 0
                                      oxane + 0
                                      pederin 0
                                      rose oxide + 0
                                      venetoclax 6
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.